AOD-9604 vs Semaglutide: Fat-Burner Peptide vs GLP-1 Weight Loss (2026)

## Quick Answer: Which One Should You Pick? **Semaglutide** wins on absolute weight loss results — clinical trials show 14-17% body weight reduction at the 2.4mg dose, versus AOD-9604's modest 4-6%. But **AOD-9604** wins on tolerability, cost, and targeted fat oxidation without appetite suppression. If your goal is significant weight loss and you can tolerate the GI side effects, semaglutide is more effective. If you want gentle fat-loss support — particularly stubborn abdominal fat — without nausea or appetite blunting, AOD-9604 is a credible alternative. A growing number of clinicians now combine the two. ## What Is AOD-9604? AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide fragment derived from the C-terminus of human growth hormone (residues 176–191). Originally developed by Australian biotech Metabolic Pharmaceuticals as an obesity treatment, it isolates the lipolytic (fat-burning) sequence of HGH while removing the growth-stimulating portion. The result is a peptide that stimulates fat breakdown without affecting blood sugar or IGF-1 levels. **How it works:** AOD-9604 binds to beta-3 adrenergic receptors in adipose tissue, triggering lipolysis (release of fatty acids from fat cells) and enhancing fat oxidation. It also appears to inhibit lipogenesis (new fat formation). Unlike full-length HGH, it does not affect blood glucose or insulin sensitivity, making it considerably safer for longer-term use. **Regulatory status:** AOD-9604 has Generally Recognized as Safe (GRAS) status in the US for food applications and is widely available through compounding pharmacies as a research peptide. It is not FDA approved as a drug. ## What Is Semaglutide? Semaglutide is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic, 2017) and chronic weight management (Wegovy, 2021). It is also available through licensed [compounding pharmacies](/products/semaglutide-001) as injectable powder for reconstitution. **How it works:** Semaglutide mimics the natural incretin hormone GLP-1, slowing gastric emptying, increasing satiety signals to the brain, and improving insulin response. The net effect is reduced appetite and substantial calorie reduction — leading to significant weight loss over months. **Clinical evidence:** The STEP-1 trial (Wilding et al., NEJM 2021) showed a mean weight loss of 14.9% over 68 weeks at the 2.4mg dose, versus 2.4% on placebo. STEP-5 demonstrated that this weight loss is sustained at 104 weeks. For complete dosing schedules, see our [semaglutide dosing guide](/guides/semaglutide-dosing-schedule-week-by-week-guide). ## Mechanism Comparison | Aspect | AOD-9604 | Semaglutide | |--------|----------|-------------| | Drug class | HGH fragment peptide | GLP-1 receptor agonist | | Primary mechanism | Stimulates lipolysis in adipose tissue | Suppresses appetite, slows gastric emptying | | Target receptor | Beta-3 adrenergic receptors | GLP-1 receptors | | Effect on appetite | Minimal | Strong reduction | | Effect on blood sugar | None | Significant improvement | | Effect on IGF-1 | None | None | | Administration | Subcutaneous, daily | Subcutaneous, once weekly | | Typical dose | 300–500mcg/day | 0.25mg → 2.4mg/week (titrated) | | Treatment pattern | Cycles of 8–12 weeks | Long-term (often continuous) | The fundamental difference: **semaglutide makes you eat less**, while **AOD-9604 helps you burn more fat from existing stores**. They operate on completely different biological pathways, which is exactly why combining them is biologically rational. ## Weight Loss Results: Head-to-Head Trial Data ### Semaglutide Clinical Results | Trial | Dose | Average Weight Loss | Duration | |-------|------|---------------------|----------| | STEP-1 (NEJM 2021) | 2.4mg/week | 14.9% (~33 lbs) | 68 weeks | | STEP-5 (Nat Med 2022) | 2.4mg/week | 15.2% sustained | 104 weeks | | SUSTAIN-7 (Lancet 2018) | 1.0mg/week | 6.1% (~13 lbs) | 40 weeks | ### AOD-9604 Clinical Results | Trial | Dose | Average Weight Loss | Duration | |-------|------|---------------------|----------| | Heffernan et al. (2007) | 1mg/day SC | 2.6 lbs over placebo | 12 weeks | | Metabolic Pharma Phase IIb | 500mcg/day | 4–6% body weight | 24 weeks | | Clinical practice (compounding) | 300–500mcg/day | 5–8 lbs typical | 8–12 week cycles | **The honest read:** Semaglutide is in a different league for raw weight loss. AOD-9604 is more of a fat-loss support peptide — useful for body recomposition, stubborn fat, or as an adjunct rather than a standalone primary weight loss intervention. ## Side Effects Profile ### Semaglutide Side Effects - **Nausea:** 11–44% during titration (mostly resolves with time) - **Diarrhea:** 8–30% - **Constipation:** 5–24% - **Vomiting:** 5–24% - **Injection site reactions:** 5–10% - **Rare serious:** pancreatitis, gallbladder events, thyroid C-cell concerns (boxed warning) See our complete [semaglutide side effects management guide](/guides/semaglutide-side-effects-how-to-manage) for evidence-based mitigation strategies. ### AOD-9604 Side Effects - **GI effects:** Essentially none - **Injection site reactions:** Minor, 3–5% - **Headaches:** Rare, mild - **Effect on blood sugar:** None - **Hypoglycemia risk:** Zero (unlike full-length HGH) This is the strongest argument for AOD-9604: an exceptional safety profile. No boxed warnings, no significant drug interactions, and no GI cascade that derails patients in the first month. ## Cost Comparison (US, 2026) | Treatment | Monthly Cost | Annual Cost | Per % Weight Loss | |-----------|-------------|-------------|-------------------| | Wegovy (brand semaglutide) | $1,349 | $16,188 | ~$1,086 per % | | Compounded semaglutide | $200–400 | $2,400–4,800 | ~$160–322 per % | | AOD-9604 (compounded) | $80–150 | $960–1,800 | ~$160–300 per % | On a "cost per percentage point of weight lost" basis, AOD-9604 and compounded semaglutide are surprisingly similar — semaglutide just produces more total weight loss. For detailed pricing comparisons by pharmacy, see our [semaglutide cost guide](/guides/semaglutide-cost-price-guide-2026). ## Combining AOD-9604 and Semaglutide A growing number of weight-loss clinicians prescribe both peptides together for patients seeking enhanced results. The rationale is biological complementarity: - **Semaglutide** reduces caloric intake (eat less) - **AOD-9604** accelerates fat oxidation (burn more existing fat) These mechanisms do not overlap, and no clinically meaningful drug-drug interactions have been documented. Patients on this combination typically report: - More aggressive body composition change than semaglutide alone - Better preservation of lean mass during rapid weight loss (a known concern with GLP-1 monotherapy) - Potential to use slightly lower semaglutide doses for equivalent results **Typical combination protocol:** - Semaglutide weekly per standard titration (0.25mg → 2.4mg) - AOD-9604 300mcg subcutaneous daily, 5–6 days per week - 8–12 week cycles with 2–4 week breaks from the AOD-9604 This combination should always be supervised by a qualified prescriber — not because of safety concerns, but because dose timing and individual response matter. ## Who Should Choose What? ### Choose Semaglutide if: - You need significant weight loss (>10% body weight) - You have type 2 diabetes or prediabetes (semaglutide improves glycemic control) - You can tolerate GI side effects during titration - You can commit to long-term use (effects partially reverse after stopping) - Insurance covers it or compounded pricing is affordable ### Choose AOD-9604 if: - You want targeted fat-loss support without appetite suppression - You cannot tolerate GLP-1 side effects (severe nausea, vomiting) - You are specifically addressing stubborn abdominal fat - You are already lean and optimizing body composition - You prefer cycled treatments over continuous therapy ### Consider Both if: - You are stalling on semaglutide alone - You want to preserve lean mass during weight loss - Your prescriber supports combination peptide therapy - You are willing to inject daily (AOD-9604 requires daily SC dosing) ## Where to Buy Safely Both peptides should only be sourced from licensed compounding pharmacies (503A or 503B) that: - Require a valid prescription - Provide Certificate of Analysis (COA) documentation per batch - Test for purity (HPLC ≥98%) - Ship cold-chain when required - Are US-based with verifiable licensing For wholesale or clinic-grade pricing on either peptide — including [batch-verified COA documentation](/coa) on every shipment — contact our team through the [wholesale inquiry form](/wholesale) or message us directly on WhatsApp at +65 9176 1341. If you are looking at semaglutide alternatives more broadly, you may also want to compare against [tirzepatide](/guides/tirzepatide-vs-semaglutide-comparison) and [retatrutide](/guides/retatrutide-vs-semaglutide-comparison), which are GLP-1 family medications with stronger weight loss outcomes than AOD-9604. --- ## References - [Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1)](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183). *New England Journal of Medicine*, 2021. - [The lipolytic action of AOD9604, a modified fragment of human growth hormone](https://pubmed.ncbi.nlm.nih.gov/15356100/). *Diabetologia*, 2004. - [The effect of AOD9604 on body composition in obese subjects: a randomized controlled trial](https://pubmed.ncbi.nlm.nih.gov/17556687/). *Diabetes, Obesity and Metabolism*, 2007. - [Two-year effects of semaglutide on body weight (STEP-5)](https://www.nature.com/articles/s41591-022-02026-4). *Nature Medicine*, 2022.